| Document Date: 2014-07-29 01:16:49
Open Document File Size: 871,78 KBShare Result on Facebook
Company Amgen Inc. / Cox / GM / / Event FDA Phase / / Facility LABORATORY MONITORING / / IndustryTerm filgrastim product / leukapheresis product / / MedicalCondition sore throat / tumor / chronic studies / cancer / hind leg dysfunction / lymphoma / bacterial infections / disease / Hodgkin’s disease / different diseases / novo acute myeloid leukemia / neutropenia / nausea / small cell lung cancer / fever / malignant melanoma / acute lymphoblastic leukemia / leukocytosis / pretreated breast cancer / febrile neutropenia / fatigue / hind limb dysfunction / synovitis / germ cell tumor / diarrhea / infection / clinical syndrome / infections / breast cancer / severe neutropenia / cyclic neutropenia / / MedicalTreatment radiation therapy / leukapheresis / red blood cell transfusions / apheresis / platelet transfusions / osteopathy / chemotherapy / bone marrow transplant / / Organization Subcutaneous administration / / Product Mesna / Cisplatin / etoposide / SC / NEUPOGEN / cyclophosphamide / Sorbitol / Ifosfamide / in / / SportsEvent NHL / / Technology Pharmacokinetics / radiation / chemotherapy / transplantation / recombinant DNA technology / DAV / /
SocialTag |
NEUPOGEN® (filgrastim) DESCRIPTION Filgrastim is a human granulocyte colony-stimulating factor (G-CSF)‚ produced by ® recombinant DNA technology. NEUPOGEN is the Amgen Inc. trademark for filgrastim‚ which has been